Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bristol, CT
NPI
1174522692
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
102 North St
Bristol, CT, 06010
Phone (860) 940-6300
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
256 services
Medicare patients, 2024
116
Average age 73
Drug cost, 2024
$1.2M
3,003 prescriptions
Company payments, 2025
$1,798
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vijay Joshi was code 99214 (office e&m - established), 138 times for 75 patients. In total Vijay Joshi billed 256 services in 6 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-02-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 138 | 75 | $78.10 | $11K |
| 99213 Office E&M - Established | Facility | 61 | 47 | $51.12 | $3,118 |
| 95251 Test - Miscellaneous | Facility | 35 | 17 | $28.18 | $986 |
| 99204 Office E&M - New | Facility | 12 | 12 | $109.07 | $1,309 |
By year: 2022 $50K for 1,278 services; 2023 $30K for 850 services; 2024 $18K for 256 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 117 | 61 | $3.17 | $370 |
Medicare prescription drug claims, 2024
In 2024, the drug Vijay Joshi prescribed most often to Medicare patients was Levothyroxine Sodium, with 273 prescriptions and refills. In total Vijay Joshi wrote 3,003 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 273 | 729 | 86 | $2,517 |
| Glimepiride Generic | 235 | 535 | 60 | $1,338 |
| Ozempic Semaglutide | 207 | 299 | 45 | $287K |
| Metformin Hcl Generic | 196 | 487 | 52 | $1,273 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 185 | 463 | 61 | $31K |
| Metformin Hcl Er Metformin Hcl | 150 | 380 | 48 | $1,492 |
| Humalog Kwikpen U-100 Insulin Lispro | 126 | 318 | 43 | $32K |
| Mounjaro Tirzepatide | 101 | 121 | 20 | $130K |
| Trulicity Dulaglutide | 93 | 140 | 19 | $141K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 91 | 240 | 29 | $13K |
| Alendronate Sodium Generic | 88 | 192 | 30 | $760 |
| Jardiance Empagliflozin | 80 | 172 | 23 | $99K |
| Novolog Flexpen Insulin Aspart | 79 | 182 | 33 | $26K |
| Synthroid Levothyroxine Sodium | 73 | 195 | 18 | $7,539 |
| Ultra-Fine Micro Pen Needle Pen Needle, Diabetic | 67 | 183 | 23 | $7,684 |
Brand drugs: 1,532 claims; generic drugs: 1,137 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vijay Joshi $1,798 ($1,798 in general payments such as food, travel and fees) from 30 companies. The largest payer was Novo Nordisk Inc with $249.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 11 | $249 |
| Lilly USA, LLC LLY | 9 | $184 |
| Amgen Inc. AMGN | 8 | $178 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $136 |
| Dexcom, Inc. DXCM | 5 | $118 |
| Abbott Laboratories ABT | 4 | $89.73 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $74.52 |
| Abbvie Inc. ABBV | 2 | $54.64 |
| Madrigal Pharmaceuticals MDGL | 2 | $53.31 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $49.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.